title: Durability of protective antibody titres is not enhanced by a two-dose schedule of an ASO3-adjuvanted pandemic H1N1 influenza vaccine in adult HIV-1-infected patients.
abstract: The immune response after influenza vaccination is impaired in HIV-infected individuals and can be enhanced by a second dose. The durability of the antibody protection and its clinical benefit is not known. We investigated clinical symptoms and antibody titres against H1N1 influenza A following no dose, 1 dose, or 2 doses of an ASO3-adjuvanted H1N1 vaccine in HIV-infected patients. Seroprotection was found in 7.9%, 52.2%, and 57.3% of patients who received no dose, 1 dose, and 2 doses of the vaccine, respectively (p-value for group comparison < 0.001), after a median of 8.2 ± 1.6 months. Clinical symptoms suggestive of an influenza-like illness were slightly more frequently reported in the unvaccinated group. Vaccinated HIV-infected patients were more likely to be seroprotected at follow-up, but there was no difference comparing those who had received 1 or 2 doses of the vaccine.
authors.affiliation: From the Department of Infectious Disease, Goethe University , Frankfurt , Germany.
authors.forename: Markus
authors.initials: M
authors.lastname: Bickel
authors.forename: Corinna
authors.initials: C
authors.lastname: Lais
authors.forename: Imke
authors.initials: I
authors.lastname: Wieters
authors.forename: Frank P
authors.initials: FP
authors.lastname: Kroon
authors.forename: Hans Wilhelm
authors.initials: HW
authors.lastname: Doerr
authors.forename: Eva
authors.initials: E
authors.lastname: Herrmann
authors.forename: Hans Reinhard
authors.initials: HR
authors.lastname: Brodt
authors.forename: Oliver
authors.initials: O
authors.lastname: Jung
authors.forename: Regina
authors.initials: R
authors.lastname: Allwinn
authors.forename: Christoph
authors.initials: C
authors.lastname: Stephan
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood*; D004338:Drug Combinations; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000821:virology; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans; D007115:Immunization Schedule; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control* / Q000821:virology; D008297:Male; D008875:Middle Aged; D011136:Polysorbates / Q000008:administration & dosage; D013185:Squalene / Q000008:administration & dosage; D014611:Vaccination / Q000379:methods*; D024502:alpha-Tocopherol / Q000008:administration & dosage
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D004338:Drug Combinations; D007252:Influenza Vaccines; D011136:Polysorbates; D013185:Squalene; C550253:AS03 adjuvant; D024502:alpha-Tocopherol
keywords: H1N1; HIV; adjuvanted; durability; pandemic